Trial Profile
A cardiac safety study of Secnidazole in healthy individuals at therapeutic and supratherapeutic doses.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Secnidazole (Primary) ; Moxifloxacin
- Indications Bacterial vaginosis
- Focus Adverse reactions
- Sponsors Symbiomix Therapeutics
- 05 Oct 2017 New trial record
- 02 Oct 2017 Results published in the Journal of Clinical Pharmacology